ААР — Американская академия педиатрии (American Academy of Pediatrics)
ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
АВСА3 — белковый член АТФ-связывающей кассеты АЗ
АВСВ11 — ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
АВСС2 — ген, кодирующий 2-й член подсемейства С ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-неврологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (Th eheterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
AC — до еды (при назначениях) — ante cibum
АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
AHA — Американская кардиологическая ассоциация (American Heart Association)
AIS — аденокарцинома in situ (adenocarcinoma in situ)
ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AUC — площадь под фармакокинетической кривой (area under the curve)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
ABCC2 - АТФ-связывающих кассет (ATP-binding cassette sub-family C member 2)
mTOR — мишень рапамицина в клетках млекопитающих (mammalian target ofrapamycin)
NB! — важно, обратить внимание (Nota bene)
NCI — Национальный институт рака (National Cancer Institute)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer)
NMDA — N-метил-D-аспартат (N-methyl-D-aspartate)
NMDA — N-метил-D-аспартатные рецепторы
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (Number Need to Treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (Pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) — post cibum рСO2 — парциальное давление углекислого газа PCSK-9 — пропротеиновая конвертаза субтилизин-кексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PD — плотность мощности (power density)
PD-1 — программируемая клеточная смерть 1 (англ. programmed cell death 1)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
PIM — показатель летального исхода у детей (Pediatric Index of Mortality)
piO2 — парциальное давление кислорода
во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы у
POP — пролапс тазовых органов (pelvic organ prolapse) POP-Q — количественная оценка пролапса тазовых органов (Pelvic Organ Prolapse Quantification)
PRISA II — оценка риска госпитализации у детей II (Pediatric Risk of Admission)
PRISM — риск летального исхода у детей (Pediatric Risk of Mortality)
PRN — при (по) необходимости (Pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS. — примечание (Post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) — quaque... hora
QAM — каждое утро (при назначениях) — quaque ante meridiem
QPM — каждый вечер (при назначениях) — quaque post meridiem
RAG — ген, активирующий рекомбиназу
REMS — Программа по оценке и снижению риска (Risk Evaluation and Mitigation Strategy)
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«+» — резус-положительный
Rh«-» — резус-отрицательный
ROCA — Алгоритм риска развития рака яичников (Risk of Ovarian Cancer Algorithm)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
ROMA — Алгоритм риска наличия злокачественной опухоли яичника (Risk of Ovarian Malignancy Algorithm)
RR — относительный риск (relative risk или risk ratio)
RW — реакция Вассермана (reaction of Wassermann)
SaO2 — сатурация артериальной крови кислородом
SatO2 — насыщение крови кислородом
SCJ — зона перехода плоского эпителия в цилиндрический (Scuamocolumnar Junction)
ScvO2 — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
SD — стандартное отклонение (standart deviation) SEER — эпидемиология эпиднадзора и данных о конечных результатах (Surveillance Epidemiology and End Result)
SFTPA — ген сурфактантного белка A
SFTPB — ген сурфактантного белка В
SFTPC — ген сурфактантного белка С
SILS — хирургия единого лапароскопического доступа (single-incision laparoscopic surgery)
В ходе подготовки статей по заболеваниям молочной железы для пользователей сайта МедУнивер использованы труды следующих авторов:
Abner AL, Connolly JL, Recht A, et al: The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 88:1072, 2000.
A’Hern RP, Jamal-Hanjani M, Szasz AM, et al: Taxane benefit in breast cancer—a role for grade and chromosomal stability. Nat Rev Clin Oncol 10(6):357, 2013.
American College of Obstetricians and Gynecologists: Breast cancer risk assessment and screening in average-risk women. Practice Bulletin No. 179, July 2017.
Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701, 2004.
Anderson TJ, Ferguson DP, Raab G: Cell turnover within “resting” human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46(3):276, 1982.
Andrade VP, Ostrovnaya I, Seshan VE, et al: Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 14:R103, 2012.
Andre F, O’Regan R, Ozguroglu M, et al: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580, 2014.
Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457, 2008.
Ashikari R, Park K, Huvos AG, et al: Paget’s disease of the breast. Cancer 26:680, 1970.
Aubele M, Werner M, Hofler H: Genetic alterations in presumptive precursor lesions of breast carcinomas. Anal Cell Pathol 24:69, 2002.
Baker SG, Lichtenstein P, Kaprio J, et al: Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics 61(1):55, 2005.
Barth RJ Jr, Wells WA, Mitchell SE, et al: A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 16:2288, 2009.
Benson EA: Management of breast abscesses. World J Surg 13:753, 1989.
Beral V, Reeves G, Bull D, et al: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103:296, 2011.
Berg WA, Campassi CI, Loffe OB: Cystic Lesions of the breast: sonographic-pathologic correlation. Radiology 227:183, 2003.
Berrington de Gonzalez A, Berg CD, Visvanathan K, et al: Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 101:205, 2009.
Berry DA, Parmigiani G, Sanchez S, et al: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227, 1997.
Bevers TB, Helvie M, Bonaccio E, et al: Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(11):1362, 2018.
Bijker N, Rutgers EJ, Duchateau L, et al: Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 91:472, 2001.
Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998, 2012.
Bodian CA, Perzin KH, Lattes R: Lobular neoplasia. Long-term risk of breast cancer and relation to other factors. Cancer 78:1024, 1996.
Boerner S, Fornage BD, Singletary E, et al: Ultrasound-guided fine-needle aspiration (FNA) of nonpalpable breast lesions. Cancer 87(1):19, 1999.
Branch-Elliman W, Golen TH, Gold HS, et al: Risk factors for Staphylococcus aureus postpartum breast abscess. Clin Infect Dis 54(1):71, 2012.
Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793, 2005.
Brenner B, Siris N, Rakowsky E, et al: Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer 87:1404, 2002.
Brohet RM, Velthuizen ME, Hogervorst FB, et al: Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 51(2):98, 2014.
Buckley ES, Webster F, Hiller JE, et al: A systematic review of surgical biopsy for LCIS found at core needle biopsy—do we have the answer yet? Eur J Surg Oncol 40:168, 2014.
Bulun SE, Simpson ER: Competitive RT-PCR analysis indicates levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 78:428, 1994.
Cabioglu N, Hunt KK, Singletary S, et al: Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg 196:354, 2003.
Cadoo KA, Traina TA, King TA: Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. Surg Oncol Clin North Am 22:823, 2013.
Cariati M, Bennett-Britton TM, Pinder SE, et al: "Inflammatory" breast cancer. Surg Oncol 14:133, 2005.
Catsburg C, Gunter MJ, Chen C, et al: Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 74:3248, 2014.
Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404, 1996.
Chaney AW, Pollack A, Mcneese MD, et al: Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89:1502, 2000.
Chang S, Parker SL, Pham T, et al: Inflammatory breast carcinoma incidence and survival. The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82:2366, 1998.
Chen YY, Hwang ES, Roy R, et al: Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol 33(11):1683, 2009.
Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643, 1994.
Coleman R, de Boer R, Eidtmann H, et al: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398, 2013.
Coopey SB, Mazzola E, Buckley JM, et al: The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat 136:627, 2012.
Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541, 1999.
Cox CE, Reintgen DS, Nicosia SV, et al: Analysis of residual cancer after diagnostic breast biopsy: an argument for fine-needle aspiration cytology. Ann Surg Oncol 2:201, 1995.
Cuzick J, Sestak I, Forbes JF, et al: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:1041, 2014.
Cvelbar M, Ursic-Vrscaj M, Rakar S: Risk factors and prognostic factors in patients with double primary cancer: epithelial ovarian cancer and breast cancer. Eur J Gynaecol Oncol 26:59, 2005.
Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707, 2011.
Davies HH, Simons M, Davis JB: Cystic disease of the breast. Relationship to carcinoma. Cancer 17:757, 1964.
Dawood S: Biology and management of inflammatory breast cancer. Expert Rev Anticancer Ther 10:209, 2010.
De Bruin ML, Sparidans J, van’t Veer MB, et al: Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239, 2009.
Degnim AC, Visscher DW, Berman HK, et al: Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25:2671, 2007.
DeLair DF, Corben AD, Catalano JP, et al: Non-mammary metastases to the breast and axilla: a study of 85 cases. Mod Pathol 26:343, 2013.
den Tonkelaar I, de Waard F: Regularity and length of menstrual cycles in women aged 41–46 in relation to breast cancer risk: results from the DOM-project. Breast Cancer Res Treat 38(3):253, 1996.
Dhillon S: Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73:475, 2013.
Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967, 2010.
D’Orsi CJ, Sickles EA, Mendelson EB, et al (eds): ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, American College of Radiology, 2013.
Dowsett M, Cuzick J, Ingle J, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509, 2010.
Dupont WD, Parl FF, Hartman WH, et al: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258, 1993.
Early Breast Cancer Trialists’ Collaborative Group, McGale P, Taylor C, et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127, 2014.
Easton DF, Pooley KA, Dunning AM, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087, 2007.
Eryilmaz R, Sahin M, Hakan Tekelioglu M, et al: Management of lactational breast abscesses. Breast 14(5):375, 2005.
Euhus DM: Genetic testing today. Ann Surg Oncol 21(10):3209, 2015.
Euhus DM, Leitch AM, Huth JF, et al: Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J 8:23, 2002.
Euhus DM, Robinson L: Genetic predisposition syndromes and their management. Surg Clin North Am 93(2):341, 2013.
Euhus DM, Uyehara C: Influence of parenteral progesterones on the prevalence and severity of mastalgia in premenopausal women. A multi-institutional cross-sectional study. J Am Coll Surg 184:596, 1997.
Evans DG, Ingham SL, Baildam A, et al: Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140:135, 2013.
Fasola CE, Chen JJ, Jensen KC, et al: Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J 24(1):66, 2018.
Feng SS, Sechopoulos I: Clinical digital breast tomosynthesis system: dosimetric characterization. Radiology 263:35, 2012.
Finch AP, Lubinski J, Moller P, et al: Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547, 2014.
Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233, 2002.
Fisher B, Costantino J, Redmond C, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581, 1993.
Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993, 1999.
Fisher B, Jeong JH, Anderson S, et al: Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823, 2004a.
Fisher ER, Land SR, Fisher B, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 100:238, 2004b.
Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676, 1998.
Foulkes WD, Metcalfe K, Sun P, et al: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029, 2004.
Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023, 2013.
Franyz VK, Pickern JW, Melcher GW, et al: Incidence of chronic cystic disease in so-called normal breast: a study based on 225 post-mortem examinations. Cancer 4:762, 1951.
Freedman AN, Yu B, Gail MH, et al: Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29:2327, 2011.
Freisinger F, Domchek SM: Clinical implications of low-penetrance breast cancer susceptibility alleles. Current oncology reports 11:8, 2009.
Fu R, Harris EL, Helfand M, et al: Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med 26:1775, 2007.
Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879, 1989.
Galimberti V, Cole BF: Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer—authors’ reply. Lancet Oncol 14:e251, 2013.
Gareth ED, Nisha K, Yit L, et al: MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145:663, 2014.
Gateley CA, Mansel RE: Management of cyclic breast pain. Br J Hosp Med 43:330, 1990.
Geisler J, Lonning PE: Aromatase inhibitors as adjuvant treatment of breast cancer. Crit Rev Oncol Hematol 57:53, 2006.
Giuliano AE, Connolly JL, Edge SB, et al: Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290, 2017.
Giuliano AE, Hawes D, Ballman KV, et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385, 2011a.
Giuliano AE, Hunt KK, Ballman KV, et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569, 2011b.
Giuliano AE, McCall L, Beitsch P, et al: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426, 2010.
Going JJ, Moffat DF: Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J Pathology 203(1):538, 2004 .
Goss PE, Ingle JN, Ales-Martinez JE, et al: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381, 2011.
Grant RN, Tabah EJ, Adair FE: The surgical significance of the subareolar lymph plexus in cancer of the breast. Surgery 33(1):71, 1953.
Greenberg JS, Javitt MC, Katzen J, et al: Clinical Performance metrics of 3D Digital breast tomosynthesis compared with 2D digital mammography for breast cancer screening in community practice. AJR Am J Roentgenol 203(3):687, 2014.
Greenberg R, Skornick Y, Kaplan O: Management of breast fibroadenomas. J Gen Intern Med 13(9):640, 1998.
Grimm SL, Seagroves TN, Kabotyanski EB, et al: Disruption of steroid and prolactin receptor pattern in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol 16:2675, 2002.
Gunter MJ, Hoover DR, Yu H, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101:48, 2009.
Gupta RK, Gaskell D, Dowle CS, et al: The role of nipple discharge cytology in the diagnosis of breast disease: a study of 1948 nipple discharge smears from 1530 patients. Cytopathology 15:326, 2004.
Haagensen CD: Gross cystic disease. In Diseases of the Breast. Philadelphia, WB Saunders, 1986, p 250.
Haas BM, Kalra V, Geisel J, et al: Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology 269:694, 2013.
Hadji P, Aapro MS, Body JJ, et al: Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546, 2011.
Haffty BG, Harrold E, Khan AJ, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471, 2002.
Halstead W: The results of operations for cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Hosp Bull 4:497, 1894.
Hankinson SE: Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24:3, 2005.
Harris EE, Schultz D, Bertsch H, et al: Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 55:1200, 2003.
Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287, 2007.
Hartmann LC, Sellers TA, Frost MH, et al: Benign breast disease and the risk of breast cancer. N Engl J Med 353:229, 2005.
Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633, 2001.
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al: Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14:3335, 2007.
Hendrick RE, Smith RA, Rutledge JH 3rd, et al: Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 22:87, 1997.
Hermansen C, Skovgaard Poulsen H, Jensen J, et al: Diagnostic reliability of combined physical examination, mammography, and fine-needle puncture ("triple-test") in breast tumors. A prospective study. Cancer 60:1866, 1987.
Houssami N, Turner R, Macaskill P, et al: An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 32:392, 2014.
Houssami N, Turner R, Morrow M: Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 257:249, 2013.
Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382, 2013.
Hulley S, Furberg C, Barrett-Connor E, et al: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58, 2002.
Hultborn KA, Larsen LG, Raghnult I: The lymph drainage from the breast to the axillary and parasternal lymph nodes, studied with the aid of colloidal Au198. Acta Radiol 45:52, 1955.
Ikeda DM, Helvie MA, Frank TS, et al: Paget’s disease of the nipple: radiologic-pathologic correlation. Radiology 189:89, 1993.
Ismail PM, Amato P, Soyal SM, et al: Progesterone involvement in breast development and tumorigenesis—as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 68:779, 2003.
Jaiyesimi IA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513, 1995.
Jatoi I: Screening clinical breast exam. Surg Clin North Am 83:789, 2003.
Johnston SR, Yeo B: The optimal duration of adjuvant endocrine therapy for early stage breast cancer—with what drugs and for how long? Curr Oncol Rep 16:358, 2014.
Jorns J, Sabel MS, Pang JC: Lobular neoplasia: morphology and management. Arch Pathol Lab Med 138(10):1344, 2014.
Kalinyak JE, Berg WA, Schilling K, et al: Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging 41:260, 2014.
Kang YD, Kim YM: Comparison of needle aspiration and vacuum-assisted biopsy in the ultrasound-guided drainage of lactational breast abscesses. Ultrasonography 35(2):148, 2016.
Karim RZ, O’Toole SA, Scolyer RA, et al: Recent insights into the molecular pathogenesis of mammary phyllodes tumours. J Clin Pathol 66:496, 2013.
Kasales CJ, Han B, Smith JS Jr, et al: Nonpuerperal mastitis and subareolar abscess of the breast. AJR Am J Roentgenol 202(2):W133, 2014.
Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26: 1331, 2008.
Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 22:79, 1997.
Khan SA, Rogers MA, Khurana KK, et al: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 89:37, 1997.
Khatcheressian JL, Hurley P, Bantug E, et al: Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961, 2013.
Kim S, Kim JY, Kim do H, et al: Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat 141:353, 2013.
King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643, 2003.
Kopans DB: Digital breast tomosynthesis: a better mammogram. Radiology 267:968, 2013.
Kotsopoulos J, Chen WY, Gates MA, et al: Risk factors for ductal and lobular breast cancer: results from the Nurses’ Health Study. Breast Cancer Res 12:R106, 2010.
Kudachadkar R, O’Regan RM: Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 55:145, 2005.
Kuehn T, Klauss W, Darsow M, et al: Long-term morbidity following axillary dissection in breast cancer patients—clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 64:275, 2000.
Kumar S, Mansel RE, Scanlon F: Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotrophin releasing hormone stimulation in cyclical mastalgia. Br J Surg 71:870, 1989.
Kvale G, Heuch I: Menstrual factors and breast cancer risk. Cancer 62:1625, 1988.
Laibl VR, Sheffield JS, Roberts S, et al: Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy. Obstet Gynecol 106:461, 2005.
Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310, 2002.
Lalloo F, Varley J, Moran A, et al: BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143, 2006.
Lau S, K?chenmeister I, Stachs A, et al: Pathological nipple discharge: surgery is imperative in postmenopausal women. Ann Surg Oncol 12:246, 2005.
Layde PM, Webster LA, Baughman LA, et al: The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group. J Clin Epidemiol 42:963, 1989.
Lee AJ, Cunningham AP, Kuchenbaecker KB, et al: BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535, 2014.
Lee CH, Dershaw DD, Kopans D, et al: Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7:18, 2010.
Lee SJ, Boscardin WJ, Stijacic-Cenzer I, et al: Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ 346:e8441, 2013.
Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78, 2000.
Locatelli I, Lichtenstein P, Yashin AI: The heritability of breast cancer: a Bayesian correlated frailty model applied to Swedish twins data. Twin Res 7(2):182, 2004.
Locker AP, Galea MH, Ellis IO, et al: Microdochectomy for single-duct discharge from the nipple. Br J Surg 75:700, 1988.
Lyman GH, Temin S, Edge SB, et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365, 2014.
Maddox PR, Mansel RE: Management of breast pain and nodularity. World J Surg 13:699, 1989.
Malone KE, Daling JR, Neal C, et al: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393, 2000.
Mansel RE, Dogliotti L: European multicenter trial of bromocriptine in cyclical mastalgia. Lancet 335:190, 1990.
Masannat YA, Husain E, Roylance R, et al: Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Breast 38:120, 2018.
Masood S: Prognostic/predictive factors in breast cancer. Clin Lab Med 25:809, 2005.
Mavaddat N, Peock S, Frost D, et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812, 2013.
Mavaddat N, Pharoah PD, Blows F, et al: Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 12:R10, 2010.
McKian KP, Reynolds CA, Visscher DW, et al: Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27:5893, 2009.
Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159, 2001.
Menes TS, Kerlikowske K, Jaffer S, et al: Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium. Cancer Epidemiol Biomarkers Prev 18(11):2822, 2009.
Merry GM, Mendelson EB: Update on screening breast ultrasonography. Radiol Clin North Am 52:527, 2014.
Metcalfe K, Gershman S, Ghadirian P, et al: Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226, 2014.
Mohammed S, Statz A, Lacross JS, et al: Granulomatous mastitis: a 10 year experience from a large inner city county hospital. J Surg Res 184(1):299, 2013.
Moller P, Stormorken A, Jonsrud C, et al: Survival of patients with BRCA1- associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat 139:155, 2013.
Monticciolo DL, Newell MS, Hendrick RE, et al: Breast cancer screening for average-risk women: recommendations from the ACR Commission on Breast Imaging. J Am Coll Radiol 14(9):1137, 2017.
Moo TA, Alabdulkareem H, Tam A, et al: Association between recurrence and re-excision for close and positive margins versus observation in patients with benign phyllodes tumors. Ann Surg Oncol 24(10):3088, 2017.
Morrell RM, Halyard MY, Schild SE, et al: Breast cancer-related lymphedema. Mayo Clin Proc 80:1480, 2005.
Morrow M, Van Zee KJ, Solin LJ, et al: Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg Oncol 23(12):3801, 2016.
Morrow M, Waters J, Morris E: MRI for breast cancer screening, diagnosis, and treatment. Lancet 378:1804, 2011.
Naeem M, Rahimnajjad MK, Rahimnajjad NA, et al: Comparison of incision and drainage against needle aspiration for the treatment of breast abscess. Am Surg 78(11):1224, 2012.
Narod SA, Iqbal J, Giannakeas V, et al: Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888, 2015.
National Comprehensive Cancer Network: Breast cancer, version 3.2018: lobular carcinoma in situ. 2018. Available at: https://www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf. Accessed February 10, 2019
Nichols HB, Berrington de Gonz?lez A, Lacey JV Jr, et al: Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564, 2011.
Oberman HA: Cystosarcoma phyllodes: a clinicopathologic study of hypercellular periductal neoplasms of the breast. Cancer 28:697, 1965.
Osin PP, Anbazhagan R, Bartkova J, et al: Breast development gives insights into breast disease. Histopathology 33:275, 1998.
Ottesen GL, Graversen HP, Blichert-Toft M, et al: Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 17:14, 1993.
Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641, 1999.
Panchal S, Bordeleau L, Poll A, et al: Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet 77:273, 2010.
Pandey TS, Mackinnon JC, Bressler L, et al: Idiopathic granulomatous mastitis—a prospective study of 49 women and treatment outcomes with steroid therapy. Breast J 20:258, 2014.
Papanicolaou GN, Holmquist DG, Bader GM, et al: Exfoliative cytology in the human mammary gland and its value in the diagnosis of breast cancer and other diseases of the breast. Cancer 11:377, 1958.
Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533, 2001.
Parks AG: The micro-anatomy of the breast. Ann R Coll Surg Engl 25:235, 1959.
Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432, 2012.
Petrakis NL, Miike R, King EB, et al: Association of breast fluid coloration with age, ethnicity and cigarette smoking. Br Cancer Res Treat 11:255, 1988.
Phipps AI, Li CI, Kerlikowske K, et al: Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev 19:1643, 2010.
Pierce LJ, Phillips KA, Griffith KA, et al: Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121:389, 2010.
Pijpe A, Andrieu N, Easton DF, et al: Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 345:2012.
Pike MC, Krailo MD, Henderson BE, et al: Hormonal risk factors, breast tissue age and the age-incidence of breast cancer. Nature 303:767, 1983.
Pilewskie M, Olcese C, Eaton A, et al: Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol 21:1552, 2014.
Ragaz J, Olivotto IA, Spinelli JJ, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116, 2005.
Rao R, Euhus D, Mayo HG, et al: Axillary node interventions in breast cancer: a systematic review. JAMA 310:1385, 2013.
Rechtman LR, Lenihan MJ, Lieberman JH, et al: Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. AJR Am J Roentgenol 202:293, 2014.
Reinfuss M, Mitus J, Duda K, et al: The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77:910, 1996.
Ringberg A, Anagnostaki L, Anderson H, et al: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514, 2001.
Risch N: The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 10:733, 2001.
Rockhill B, Spiegelman D, Byrne C, et al: Validation of the Gail model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358, 2001.
Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321, 2002.
Rouzier R, Pronzato P, Chereau E, et al: Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat 139:621, 2013.
Russo IH, Russo J: Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938, 1996.
Sadek BT, Shenouda MN, Abi Raad RF, et al: Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary? Int J Radiat Oncol Biol Phys 87:726, 2013.
Salvadori B, Bartoli C, Zurrida S, et al: Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 27:35, 1991.
Santen RJ, Mansel R: Benign breast disorders. N Engl J Med 353:275, 2005
Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75, 2010.
Sasson AR, Fowble B, Hanlon AL, et al: Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 91:1862, 2001.
Savage JL, Jeffries DO, Noroozian M, et al: Pleomorphic lobular carcinoma in situ: imaging features, upgrade rate, and clinical outcomes. AJR Am J Roentgenol 211(2):462, 2018.
Schelfhout VR, Coene ED, Delaey B, et al: Pathogenesis of Paget’s disease: epidermal heregulin-alpha, motility factor, and the HER receptor family. J Natl Cancer Inst 92(8):622, 2000.
Seeley RR, Stephens TD, Tate P: Reproductive system. In Anatomy and Physiology, 7th ed. New York, McGraw-Hill, 2006, p 1058.
Seynaevea C, Verhooga LC, van de Boscha LM, et al: Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150, 2004.
Shaaban M, Barthelmes L: Benign phyllodes tumours of the breast: (over) treatment of margins — a literature review. Eur J Surg Oncol 43(7):1186, 2017.
Shannon J, Douglas-Jones AG, Dallimore NS: Conversion to core biopsy in preoperative diagnosis of breast lesions: is it justified by results? J Clin Pathol 54:762, 2001.
Sickles EA, Klein DL, Goodson WH, et al: Mammography after needle aspiration of palpable breast masses. Am J Surg 145:395, 1983.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1):7, 2019.
Skaane P, Bandos AI, Gullien R, et al: Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 267:47, 2013.
Smith BD, Arthur DW, Buchholz TA, et al: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74:987, 2009.
Smith RA, Andrews KS, Brooks D, et al: Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68(4):297, 2018.
Sneige N, Wang J, Baker BA, et al: Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 15:1044, 2002.
Soderqvist G, Isaksson E, von Schoultz B, et al: Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176:123, 1997.
Solin LJ, Kurtz J, Fourquet A, et al: Fifteen-year results of breast-conserving surgery and breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754, 1996.
Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721, 2008.
Stafford I, Hernandez J, Laibl V, et al: Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 112:533, 2008.
Stavros AT, Thickman D, Rapp CL, et al: Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 196:123, 1995
Stoeckelhuber M, Stumpf P, Hoefter EA, et al: Proteoglycan-collagen associations in the non-lactating human breast connective tissue during the menstrual cycle. Histochem Cell Biol 118(3):221, 2002.
Tabbara SO, Frost AR, Stoler MH, et al: Changing trends in breast fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Survey. Diagn Cytopathol 22:126, 2000.
Tai YC, Domchek S, Parmigiani G, et al: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99:1811, 2007.
Tan BY, Acs G, Apple SK, et al: Phyllodes tumours of the breast: a consensus review. Histopathology 68(1):5, 2016.
Taylor G, Meltzer A: Inflammatory carcinoma of the breast. Am J Cancer 33:33, 1938.
Thomas DB, Gao DL, Ray RM, et al: Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94:1445, 2002.
Thomsen AC, Hansen KB, Moller B: Leukocyte counts and microbiological cultivation in the diagnosis of puerperal mastitis. Am J Obstet Gynecol 146: 938, 1983.
Tolaney S: New HER2-positive targeting agents in clinical practice. Curr Oncol Rep 16:359, 2014.
Tremblay-LeMay R, Hogue JC, Provencher L, et al: How wide should margins be for phyllodes tumors of the breast? Breast J 23(3):315, 2017.
Trudeau M, Charbonneau F, Gelmon K, et al: Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886, 2005.
Turnbull L, Brown S, Harvey I, et al: Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 375:563, 2010.
Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111, 2004.
Urban J, Egeli R: Non-lactational nipple discharge. CA Cancer Journal Clin 28:3, 1978.
U.S. Preventive Services Task Force: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151(10):716, 2009.
Vandenbussche CJ, Khouri N, Sbaity E, et al: Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively. Am J Surg Pathol 37:913, 2013.
Vihko RK, Apter DL: The epidemiology and endocrinology of the menarche in relation to breast cancer. Cancer Surv 5:561, 1986.
Virnig BA, Tuttle TM, Shamliyan T, et al: Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102:170, 2010.
Vogel VG, Costantino JP, Wickerham DL, et al: Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 3: 696, 2010.
von Minckwitz G: Neoadjuvant therapy: what are the lessons so far? Hematol Oncol Clin North Am 27:767, 2013.
Wai CJ, Al-Mubarak G, Homer MJ, et al: A modified triple test for palpable breast masses: the value of ultrasound and core needle biopsy. Ann Surg Oncol 20:850, 2013.
Watt-Boolsen S, Rasmussen NR, Blichert-Toft M: Primary periareolar abscess in the non-lactating breast: risk of recurrence. Am J Surg 155:571, 1987.
Wazir U, Wazir A, Wells C, et al: Pleomorphic lobular carcinoma in situ: current evidence and a systemic review. Oncol Lett 12(6):4863, 2016.
Welch HG, Passow HJ: Quantifying the benefits and harms of screening mammography. JAMA Intern Med 174:448, 2014.
Welsh ML, Buist DS, Aiello Bowles EJ, et al: Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat 114:549, 2009.
Wilkie C, White L, Dupont E, et al: An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 190:563, 2005.
Wrensch WR, Petrakis NL, Gruenke LD, et al: Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Br Cancer Res Treat 15:39, 1990.
Zhou WB, Xue DQ, Liu XA, et al: The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 137:1053, 2011.
Труды отечественных авторов при подготовке статей по гинекологии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
